HOME >> BIOLOGY >> NEWS
Study shows drug blocks breast cancer migration to bone

An international research team has identified what may be a critical molecule in the ability of tumours to metastasize -- or spread -- into bone. The research, initiated at the University of Toronto and continued at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, found that a protein in bone called RANKL appears to communicate with a receptor in breast, prostate and skin cancer cells -- telling them to migrate. Moreover, a drug already known to block RANKL's activity may prevent cancers from spreading into the bone.

Roughly 120 years ago, scientists predicted that bone tissue might manufacture certain molecules that entice cancer cells to lodge there. More people die of metastases -- secondary tumours that develop elsewhere in the body -- than from their initial tumours and bone is particularly fertile "soil" for travelling cancer "seed" cells. It has been estimated that 70 per cent of patients with progressive breast cancer and 84 per cent of prostate cancer patients develop bone metastases.

D. Holstead Jones, a former post-doctoral fellow in Professor Josef Penninger's laboratory of medical biophysics and immunology at U of T, is the lead author of the paper, which appears in the March 30 issue of the journal Nature. The team also included researchers from the University of Western Ontario's Department of Physiology and Pharmacology. Josef Penninger is currently the director of the IMBA in Vienna, where the project is being continued.

Jones and her colleagues show that RANKL, a cytokine protein which is produced at high levels in bone marrow, acts on breast, prostate and skin cancer cells through the RANK receptor. Over the past few years, Penninger's lab had determined that RANKL is essential in both bone breakdown and in controlling the growth of cells that form a lactating mammary gland. Putting these two discoveries together, the team decided to study the link between breast cancer and bon
'"/>

Contact: Nicolle Wahl
nicolle.wahl@utoronto.ca
416-978-6974
University of Toronto
29-Mar-2006


Page: 1 2 3

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/30/2020)... Ontario (PRWEB) , ... January 30, 2020 , ... ... with an eye on the Canadian market, is pleased to announce that the company ... of growth since the company launched in 2017. , “We are so thrilled ...
(Date:1/29/2020)... ... January 29, 2020 , ... ... vitro toxicology testing solutions, has announced a record earnings year for 2019. With ... showed more than a twenty percent increase in revenue and a thirty percent ...
(Date:1/28/2020)... CAMBRIDGE, Mass. (PRWEB) , ... January 28, 2020 ... ... problems for life sciences companies and government agencies, announced that the firm has ... in the country. Tunnell’s Cambridge office will be in the Cambridge Innovation Center ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... Genedata, ... the release of Genedata Expressionist ® 13.5 at the 2020 WCBP ... Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their ...
(Date:1/24/2020)... ... January 24, 2020 , ... The ... in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades ... the world. And as Slone Partners celebrates its 20th anniversary this ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... precision of Genome editing. The partners have agreed to co-develop and market a ... research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop ...
(Date:1/8/2020)... ... January 08, 2020 , ... Anomet Products ... specific properties for use in harsh environments inside or outside of the human ... three metals or alloys to achieve specific properties such as corrosion-resistance, biocompatibility, or ...
Breaking Biology Technology:
Cached News: